^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | FT516 (NK cell stimulant, CD16 agonist) |
| Direction: | Sensitive |
Evidence:
Title:
Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL
Published date:
12/13/2021
Excerpt:
...the Company today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to FT516 for the treatment of relapsed / refractory diffuse large B-cell lymphoma (DLBCL).
